Loading organizations...
§ Private Profile · Gent, BE
Tanai Therapeutics is a technology company.
Tanai Therapeutics develops first-in-class small molecules engineered to increase energy expenditure in a tissue-selective manner. The company’s approach is rooted in advanced biological understanding, leveraging human genetics and sophisticated animal models to guide its mechanism of action. This precise methodology targets the underlying physiological processes implicated in metabolic dysfunction.
The company was established in 2023 as a spin-off from the VIB-UGent Center for Inflammation Research, building upon foundational research by Professor Savvas Savvides. This scientific insight, focusing on novel pathways to modulate energy metabolism, formed the impetus for Tanai Therapeutics' formation, supported by a consortium of notable life science investors and institutions.
Tanai Therapeutics’ work is directed towards individuals afflicted with obesity and a range of related cardiometabolic diseases. The company's overarching vision is to transform metabolic health by developing innovative therapies that restore balance through controlled energy expenditure, ultimately aiming to improve patient outcomes and redefine treatment paradigms for these widespread conditions.
Tanai Therapeutics has raised $4.0M across 1 funding round.
Tanai Therapeutics has raised $4.0M in total across 1 funding round.
Tanai Therapeutics is a Belgian biotechnology company developing a first-in-class oral therapeutic for obesity, targeting a novel, genetically validated pathway that boosts energy expenditure to promote selective fat loss while preserving muscle mass.[1][2][3][5] Founded in 2023 as a spin-off from the VIB-UGent Center for Inflammation Research, it addresses unmet needs in obesity treatment—unlike GLP-1 mimetics like Wegovy that suppress appetite—by focusing on sustainable fat reduction with potentially fewer side effects such as muscle loss or rebound weight gain.[1][2] The company serves individuals with obesity and related complications like type 2 diabetes and cardiovascular disease, tackling a global epidemic projected to affect over 4 billion people by 2035.[1][2] Growth momentum includes over €6 million in seed financing from investors like V-Bio Ventures, Qbic, VIB, BioGeneration Ventures, and Novo Nordisk, plus the appointment of experienced CEO Pieter Rottiers in January 2025 to advance toward in-vivo proof-of-concept studies.[5][6]
Tanai Therapeutics emerged in 2023 from proprietary discoveries at the VIB-UGent Center for Inflammation Research by Prof. Savvas Savvides and Prof. Charlotte Scott, who identified a groundbreaking mechanism for obesity treatment.[1][2][5] Launched as a VIB spin-off on November 13, 2023, with initial seed funding from V-Bio Ventures (lead), Qbic, and VIB, the company quickly expanded its round to over €6 million by September 2024 with additions from Novo Nordisk and BioGeneration Ventures.[2][4][6] Early traction came from VIB's drug discovery team de-risking the target, positioning Tanai to enter the competitive obesity market with a differentiated oral therapy.[2][3] In January 2025, biotech veteran Pieter Rottiers was appointed CEO, bringing over 20 years of experience from roles like leading Precigen ActoBio's clinical programs in gastrointestinal and autoimmune disorders.[5]
Tanai rides the explosive growth in obesity therapeutics, a market transformed by GLP-1 successes like Wegovy, which drive 20% weight loss but leave gaps in muscle preservation and oral options.[2][3] Timing is ideal amid rising demand for next-generation treatments, as obesity fuels 4 million annual deaths and risks for metabolic diseases, with projections of 4 billion affected by 2035.[1][2] Favorable forces include surging investor interest—evident in Novo Nordisk's early equity stake via its Science2Medicine program—and biotech hubs like Ghent fostering spin-offs.[5][6] Tanai influences the ecosystem by pioneering energy-expenditure approaches, potentially complementing incretin mimetics and expanding sustainable options in cardiometabolism.[2][6]
Tanai is poised to advance its lead candidate through in-vivo proof-of-concept and clinical stages, leveraging its €6M+ funding and Rottiers' leadership to secure further capital.[1][5][6] Key trends like combo therapies, oral innovations, and muscle-sparing drugs will shape its path, especially as GLP-1 limitations (e.g., side effects, adherence) create openings.[2] Its influence may grow by validating new targets, partnering with giants like Novo Nordisk, and delivering a transformative oral therapy—revolutionizing obesity care from a VIB-rooted biotech powerhouse.[1][5][6] This positions Tanai as a high-potential player in the obesity epidemic's next chapter, building on its selective fat-loss promise.
Tanai Therapeutics has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Seed in September 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2024 | $4M Seed | — | BGV (biogeneration Ventures) | Announced |
Tanai Therapeutics has raised $4.0M in total across 1 funding round.
Tanai Therapeutics's investors include BGV (BioGeneration Ventures).